• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline upd

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline upd

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户：winterdxm7124
【摘 要】
：
Purpose: To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.Methods: AnUpdate Co
【作 者】
：
J.Douglas Rizzo Melissa Brouwers Patricia Hurley Jerome Seidenfeld Murat O.Arcasoy Jerry L.Spivak Charles L.Bennett Julia Bohlius Darren Evanchuk Matthew J.Goode Ann A.Jakubowski David H.Regan Mark R. 
【机 构】
：
Medical College of Wisconsin, Milwaukee, WI McMas
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
【发表日期】
：
2012年12期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Purpose: To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.Methods: AnUpdate Committee reviewed data published between January 2007 and January 2010.MEDLINE and the Cochrane Library were searched.Results: The literature search yielded one new individual patient data analysis and four literature-based metaanalyses, two systematic reviews, and 13 publications reporting new results from randomized controlled trials not included in prior or new reviews.
其他文献
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Work
Introduction Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree
会议
anaemiaerythropoiesis stimulating agentsbiosimilarsguidelinespure red cell a
Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key i
Introduction Despite major recent therapeutic improvements, septic shock remains a leading cause of mortality in intensive care patients [1].For more than a decade, it has been advocated [2,3] that th
会议
acute kidney injuryadsorptionhaemofiltrationsepsisseptic shock
Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa
会议
anaphylactoid reactionsDeclaration of Helsinkiiron deficiencyhemodialysisiro
Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who
会议
Hypersensitivity reactions and deaths associated with intravenous iron preparations
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans
会议
hypersensitivity reactionsintravenous ironiron dextraniron sucrosesodium fer
Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous
Bacterial sepsis is the second leading cause of death among hemodialysis (HD) patients.Iron overload and intravenous iron therapy are linked to bacterial infection.This study examined iron stores, int
会议
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.Background.Iron is essential for the formation of hemoglobin.During long-term treatment with human recombinant ery
会议
ironchronic kidney failureneutrophilsrandomized controlled trial
Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia th
The medical care of renal anaemia has received much attention over the past decade, as nephrologists have recognized the increased therapeutic value of erythropoiesis-stimulating agents.The European B
会议
epoetinhaemodialysisinfectioninflammationironrenal anaemia
Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disea
Background and objectives: Optimal hemoglobin targets for chronic kidney disease patients receiving erythropoiesisstimulating agents remain controversial.The effects of different hemoglobin targets on
会议
Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure
Background.Intravenous iron is a recognized therapy of anaemia in chronic haemodialyzed patients,especially in those receiving erythropoietin (Epo),while its role in the anaemia of pre-dialyzed chroni
会议
anaemiachronic renal failureiron therapypre-dialysis